Status:
RECRUITING
Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Pancreatic Ductal Adenocarcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This clinical trial investigates the nutrients pancreatic cancers depend on in which to survive and the processes these tumors use (metabolism) to obtain these nutrients. Giving U-13C-glucose during s...
Detailed Description
PRIMARY OBJECTIVE: I. To describe and discover new insights into the glucose, tricarboxylic acid (TCA) cycle, amino acid, and lipid metabolic dependencies of pancreatic ductal adenocarcinoma (PDAC) v...
Eligibility Criteria
Inclusion
- Male or female patients \>= 18 years of age
- Pancreatic adenocarcinoma patients, previously diagnosed by biopsy, who are candidates for intended curative resection either with or without neoadjuvant chemotherapy
- Willing to undergo mandatory intraoperative small excisional and core biopsies (4-6 passes) of tumor and normal tissue for research purposes at the time of proposed pancreatectomy
- 16 patients will be enrolled including 8 with no prior treatment and 8 treated with at least 3 months of neoadjuvant chemotherapy
- All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry
Exclusion
- Patients receiving any anti-cancer therapy (chemotherapy, immunotherapy, and/or biologic therapy) for 8 patients; the other 8 patients will be treated with neoadjuvant chemotherapy but no radiation, biologic or immunotherapy prior to surgery
- Is currently enrolled, or will enroll in, a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study
- Concomitant active malignancy
- Is of child-bearing potential who has not had a recent negative pregnancy test done outside of this clinical trial (i.e., as part of standard preparation for diagnosis and treatment for her cancer)
Key Trial Info
Start Date :
March 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT05296421
Start Date
March 14 2022
End Date
July 1 2026
Last Update
April 10 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Cooperman Barnabas Medical Center (Saint Barnabas Medical Center)
Livingston, New Jersey, United States, 07039
2
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08903